# Oisin Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oisin-biotechnologies

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.oisinbio.com
- Total disclosed funding: $10M
- Latest round: Series A (Jun 28, 2024)
- Investors on record: 2

## About

Oisin Biotechnologies is a biotech firm focused on developing innovative genetic medicines to tackle age-related conditions, utilizing proprietary delivery technologies for enhanced therapeutic outcomes.Founded in 2014 in Seattle, US, Oisin Biotechnologies is dedicated to creating genetic therapies aimed at age-related health issues. The company recently raised USD 5.38 mn in Series A funding led by AbbVie Biotech Ventures. The firm has completed 3 deals to date, with its most recent deal occurring on June 28, 2024. The company’s leadership includes CEO Matthew Scholz, who is among the founders Kevin Perrott and Matthew Scholz.Oisin Biotechnologies specializes in pioneering genetic medicines designed to address age-related conditions. Highlighting their offerings is the patented Fusogenix™ Proteo-Lipid Vehicle (PLV), a non-viral delivery system that enhances the distribution of DNA and RNA payloads. Their product pipeline targets frailty, muscle growth, fat cell elimination, and senescent cell removal, serving a varied clientele that includes healthcare providers and pharmaceutical partners primarily in the US and selected markets in Europe and Asia.Oisin Biotechnologies generates revenue through partnerships and collaborations with health and pharmaceutical organizations, focusing on B2B transactions. Their model includes licensing agreements and research collaborations, allowing clients access to proprietary technologies and therapeutic programs. Revenue structures involve milestone payments, royalties, or subscription-based access to their platforms, particularly from their flagship product, Fusogenix™ PLV, which addresses aging-related health challenges.Following the recent Series A funding of USD 5.38 mn, Oisin Biotechnologies plans to advance its treatments for age-related diseases towards human trials. The company is set to explore new markets in both Europe and Asia, aiming for expansion by 2025. This funding will significantly support their ongoing development and operational strategies as they work on launching new products targeting aging-related conditions.

## Funding rounds

- Series A, Jun 28, 2024, $5.4M — AbbVie Ventures
- Seed, May 27, 2021, $5M — Althea Group Ventures

## Investors

- Althea Group Ventures (https://capitalatlas.ai/funds/althea-group-ventures) — Seed
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A